ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lonza will enter the sterile drug fill-and-finish business by acquiring a Novartis facility in Stein, Switzerland. The facility includes liquid and lyophilized dosage-form capacity for clinical and commercial supply. Lonza will produce for Novartis and for third parties. The deal continues a trend among pharmaceutical services firms to build up finished-drug manufacturing capacity. Last month Catalent said it will acquire Bristol-Myers Squibb’s solid, biologics, and sterile product facility in Anagni, Italy.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X